98%
921
2 minutes
20
Astrocytes play a key role in modulating synaptic transmission by controlling the available extracellular GABA via the GAT-1 and GAT-3 GABA transporters (GATs). Using primary cultures of rat astrocytes, we show here that an additional level of regulation of GABA uptake occurs via modulation of the GATs by the adenosine A(1) (A(1)R) and A(2A) (A(2A)R) receptors. This regulation occurs through a complex of heterotetramers (two interacting homodimers) of A(1)R-A(2A)R that signal via two different G-proteins, G(s) and G(i/o), and either enhances (A(2A)R) or inhibits (A(1)R) GABA uptake. These results provide novel mechanistic insight into how G-protein-coupled receptor heteromers signal. Furthermore, we uncover a previously unknown mechanism in which adenosine, in a concentration-dependent manner, acts via a heterocomplex of adenosine receptors in astrocytes to significantly contribute to neurotransmission at the tripartite (neuron-glia-neuron) synapse.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6623011 | PMC |
http://dx.doi.org/10.1523/JNEUROSCI.2526-11.2011 | DOI Listing |
Structure
August 2025
Key Laboratory of Biomacromolecules (CAS), National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Electronic address:
GABA (g-aminobutyric acid) transporter 3 (GAT3) is primarily found in glial cells and is essential for regulating GABA homeostasis in the central nervous system by mediating GABA uptake. Consequently, GAT3 has emerged as a significant therapeutic target for the treatment of epilepsy. In this study, we present the cryoelectron microscopy (cryo-EM) structures of GAT3 bound to its substrate GABA, the selective inhibitor SNAP-5114, and in the substrate-free state.
View Article and Find Full Text PDFMol Psychiatry
September 2025
Department of Psychiatry and Behavioral Sciences, University of California, Davis, CA, USA.
Background: Anxiety disorders (AnxDs) are highly prevalent and often untreated or unresponsive to treatment. Although proton magnetic resonance spectroscopy (1H-MRS) studies of AnxDs have been conducted for over 25 years, a consensus regarding neurometabolic abnormalities in these conditions is lacking.
Methods: A systematic review and meta-analysis of 1H-MRS studies of AnxDs (social anxiety disorder, generalized anxiety disorder, and panic disorder) identified 25 published datasets meeting inclusion criteria.
J Nucl Med
September 2025
PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
The main inhibitory neurotransmitter in the central nervous system is γ-aminobutyric acid (GABA). GABA transporter type 1 (GAT-1) is the principal GABA transporter in the brain, and it plays a crucial role in modulating GABA signaling. Its potential role in several neuropsychiatric disorders makes it an important target to study.
View Article and Find Full Text PDFPhysiol Mol Biol Plants
July 2025
Plant Physiology and Biochemistry Research Laboratory, Department of Botany, University of Kashmir, Srinagar, 190006 India.
Unlabelled: Oxidative stress mediated by reactive oxygen species and the concomitant antioxidant defenses orchestrate the senescence trajectory in ethylene-insensitive flowers. This investigation delineates the potential of γ-Aminobutyric acid (GABA) in ameliorating oxidative damage and impeding senescence in detached scapes of , an ethylene-insensitive flower system. The delayed senescence and enhanced scape performance were attributed to the upregulation of antioxidant enzyme activities, including superoxide dismutase, catalase and ascorbate peroxidase, which were elevated by 52.
View Article and Find Full Text PDFFront Psychiatry
August 2025
Standardization of Computational Anatomy Techniques for Cognitive and Behavioral Sciences (SoCAT) Lab, Department of Psychiatry, Faculty of the Medicine, Ege University, Izmir, Türkiye.
Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emerging pharmacologic treatments for MDD, focusing on their mechanisms of action, clinical effectiveness, and potential to fill the gaps left by conventional therapies.
View Article and Find Full Text PDF